

INDEX

- 4-hydroperoxycyclophosphamide 234, 241, 249, 271
- 5 azacytidine 175
- acute lymphoid leukemia 355
- acute lymphoblastic leukemia (ALL) 113, 134, 196, 205, 223, 266, 277, 296, 355
 - allogeneic bone marrow transplantation 387
 - chemotherapy 205, 387
 - high risk 271
 - standard risk 271
- acute myeloblastic leukemia 58, 211, 223, 295
 - allogeneic bone marrow transplantation 387
 - chemotherapy 387
- acute promyelocytic leukemia 151
- adenovirus 311
- AdOAP 152
- adoptive transfer of humoral immunity 328
- adult respiratory disease syndrome 311
- age of the patient 154
- alkyl-lysophospholipides 250
- ALL 126
 - chemotherapy 196
 - chromosomal abnormalities 199
 - chromosome abnormalities 202
 - colonies 142
 - colony formation 144
 - immunological phenotype 201
 - immunophenotype 198, 208
 - prognostic factors 198, 199
- allogeneic bone marrow transplantation 168, 211, 221, 234, 295, 345, 355
 - acute GMD 298
 - acute leukemia 277
 - acute lymphoblastic leukemia 296, 318, 387
 - acute myeloblastic leukemia 295, 318, 387
 - ALL 181
 - chronic GMD 298
 - chronic GVHD 320
 - chronic myelogenous leukemia 277
 - complications 320
 - cyclosporin prophylaxis 298
 - early relapse 298
 - extramedullary disease 298
 - FAB classifications 298
 - GvHD 349
 - graft-versus-host disease 297
 - haplo identical 277
 - hemopoietic repopulation 350
 - HLA - identical 277
 - HLA match 297, 318, 346
 - HLA mismatch 297, 346
 - first remission 296
 - relapse 319
 - second remission 296
 - the acute leukemias 305
 - in third remission 296
 - late relapse 298
 - long-term follow up 318
 - mismatched 277
 - myelotrexat prophylaxis 298
 - prevention of GvHD 345, 355
 - prognostic factors 295
 - recurrence of leukemia 320
 - relapse of leukemia 297, 350
 - remission 319
 - soybean lectin agglutination 345
 - survival 318, 350
 - T cell of leukemia 297
 - T-cell depletion 345, 349, 355
- allogeneic marrow transplantation 318
- allogeneic transplantation for ALL 305
- allogeneic transplantation for ANLL 307
- AML precursors 68
- AML-CFU 68
- AMSA 151, 159
- AMSA-OAP 152
- anti-IL2 receptor 142
- antithymocyte globulin 339
- asta-Z-7557 249, 254, 257
- asta-Z-7654 249
- autologous 62
- autologous bone marrow transplantation 211, 234, 248, 266, 271, 275, 288
 - acute lymphoblastic leukemia 241, 266, 271, 275
 - acute myeloblastic leukemia 241, 248
 - acute myeloblastic leukemia 221, 234
 - chemotherapy purging 222, 234, 241, 248, 271
 - diving relapse clonogenic cells 213
 - double grafting 221
 - immunological purging 241, 271
 - impurged marrow 221
 - in first remissions 215, 242, 260
 - in immunological purging 266, 275
 - in partial remission 260
 - in second remission 215, 239, 242, 260
 - in third remission 240, 242
 - leukemia purging 289
 - merocyanine 540 288, 289
 - mouse 289

- non-purges marrow 211
- photolysis (purging) 288
- photolysis 289
- photosensitized 289
- purging 289
- purging leukemia 288
- purging tumor cells 288
- toxicity 215, 225, 236, 241, 268, 271
- tumor cells purging 289
- B-ALL 114, 198, 200, 208, 299
- basic growth curves for data analysis 100
- BFU-E 252, 358
- blast fraction sorted 80
- bleomycin 249
- BN acute myelocytic leukemia (BNML) 76
- BN rat leukemia 253
- BN rat leukemia model 98
- bone marrow transplantation 365
 - histoincompatible 363
 - in first remission 295
 - rhetus monkeys 363
 - T-lymphocyte depletion 364
- breakpoint analysis in cml 12
- breakpoint cluster region 12
- brown norway rat acute myelocytic leukemia 97
- brown norway rat leukemia 86
- c-abl 12
- c-ets-1 1
- c-myc 1, 55
- c-sis 4
- calla 118
- cDNA libraries 13
- cDNA library 15
- cell line 251
- cell lines 254
- CFU-E 287
- CFU-GEMM 252, 287, 288
- CFU-GM 252, 254, 287, 347, 357, 358
- CFU-Meg 287
- CFU-S 252, 253, 287
- CFY-GM 68
- chemotherapy 386
- chromosomal 2
- chromosome abnormalities 208
- chromosome 1
- chromosome-8 55
- chromosome-14 55
- chromosome-18 55
- chromosome-21 40
- chronic graft-versus-host disease 320
- chronic myeloid leukemia 355
- chronic pulmonary failure 311
- clonogenic AML cells 62
- clonogenic cellos 387
- clonogenic leukemic cells 261
- clonogenic leukemia stem cell assays (LCFU-S) 98
- colony assay 251
- colony culture assays 68
- colony forming cells photolysis 287
- common acute lymphoblastic leukemia 266
- common ALL 114, 198, 200, 201
- common ALL antigen (CALLA) 115
- computer simulation studies 98
- conditioning regimen 221
- congenital 32
- consolidation therapy 171
- counterflow centrifugation 357
- cox model 186
- coxackie virus 311
- curve fitting 103
- cytofluorographic analysis 71
- cytogenetic analyses 387
- cytogenetic in predicting outcome 154
- cytogenetic markers 1
- cytogenetic profile 154
- cytogenetics 155
- cytomegalovirus (CMV) infections 330
- daudi cell line 251, 288
- detection limit 121, 126
- detection of AML 58
- detection of CML cells 20
- detection of minimal disease 282
- differentiation antigens 68, 113
- DNA histograms 79
- DNA rearrangements 51
- dose-survival bioassays 99
- double IF staining 121
- double immunofluorescence 115
- down's 33
- E_{AET} resette depletion 338
- elevation of uric acid 154
- elutration 355
- engraftment 328, 365
- enteroviral infections 311
- EORTC leukemia - lymphoma group 164
- etoposide 249
- ets genes 23
- ets-1 27
- ets-2 27
- exponential phase 100, 107
- exponential growth with time delay 100
- flow cytometry 99, 387
- fluorescence activated cell sorting (FACS) 68

- forward- and perpendicular light scatter 80
 fucose binding lectin 69
- genetics of T-cell recognition 374
 Gompertz equation 100
 goodness of fit criteria 103
 gradual drug influence model 107
 graft rejection 343, 374
 graft versus host disease (GvHD) 234,
 275, 277, 295, 323, 329, 337, 349,
 355, 374, 388
 graft versus host reaction 212, 365
 graft versus leukemia 212, 221, 243, 376,
 387, 388
 growth fraction 100
 growth kinetics of minimal residual
 disease 97
 growth rate 100
 GVHD 311
- high dose ara-C 209, 210
 high dose cytosine arabinoside 159, 205
 high risk ALL 387
 histoincompatible bone marrow transplan-
 tation 363
 history of a prior malignancy 154
 history of an antecedent hematologic
 disorder 154
 HL-60 cell line 251, 257, 288
 HLA mismatched transplants 379
 host v graft (graft rejection) 331
 hybrid resistance 343
 hypodiploid abnormalities 185
- ig gene rearrangements 51, 55
 IL2 receptor expression 141
 immune reconstitution 328
 immunoglobulin isotype recovery 328
 immunological AML subclassification 59
 immunological marker analysis 113
 immunotoxin 241, 276, 277, 278
 IMR-32 cell line 288
 in situ hybridization 2, 26, 387
 in vitro colony assays 141, 287
 induction chemotherapy 386
 induction of membrane receptors for IL2
 142
 initial cytoreduction 174
 instantaneous drug influence model 106
 intensive consolidation 167
 interstitial pneumonitis 311
 intrathecal 180
 intraventricular methotrexate 180
 isolation of probes 12
- K-562 288
 K-562 cell line 251
 kappa-lambda ratio 115
 kappalambda ratio 115
 kinetic behaviour of leukemic cells 79
 kinetics of distribution of leukemic cells
 80
 kinetics of minimal residual disease 76
- L-CFU 141
 L1210 leukemia 288, 289
 lactic dehydrogenase level 150
 LCFU-S 77
 least squares optimization routines 104
 leukaemic relapse 330
 leukemia 32
 leukemia clonogenic cells 213
 leukemia regrowth 84
 leukemic cell frequency in various bones
 81
 leukemic clonogenic cells 243, 250, 251,
 261, 386
 leukemic colony-forming cells (L-CFC)
 62
 leukemic homogenic cells 241
 light activated cell sorter 77
 limiting dilution analysis (LDA) 375
 limiting dilution assay 251
 logistic regression model 154
 long period of symptoms prior to
 diagnosis 154
 low numbers of ALL cells 126
 lymphokines 329
- mafosfamide 254
 mafosfamide-L-lysine 249
 major histocompatibility complex 374
 mapping of specific genes 2
 marker density 68
 marrow graft rejection 380
 marrow transplantation across the major
 histocompatibility complex 374
 marrow transplantation for endstage acute
 leukemia 295
 mathematical models for the description of
 the growth 104
 mefosfamide-cyclohexylamine 249
 membrane fluidity 283
 merocyanine 250
 merocyanine-540 282
 merocyanine-540 purging of leukemia 291
 merocyanine-540 purging of tumor cells
 291
 merocyanine-540 toxicity 291
 MHC incompatibility 377
 MHC incompatible bone marrow transplan-
 tation 364

- minor histocompatibility antigens 374
- mixed lymphocyte culture (MLC) 377
- monoclonal antibodies (MCA) 58, 68, 142
- monoclonal antibody (MCA), RM124 99
- monoclonal antibody B1 267
- monoclonal antibody J2 267
- monoclonal antibody J5 267
- multivariate analysis to identify factors 154
- myasthenia gravis 310
- myeloid engraftment 379
- myeloid surface antigens 58
- myeloid transformation gene(s) 33

- N-dodecylmorpholine 250
- Namalwa cell line 251
- nitrogen mustard (HN2) 249
- NK cell phenotype and function 328
- non cross-resistance 164
- non-homogeneous distribution of leukemic cells 80
- normal myeloid precursors 68
- Northern blot 14
 - hybridizations 13
- nucleotide sequences 30
- null ALL 114, 200, 201, 299

- oncogene 1, 55

- percent of abnormal cells on cytogenetic analysis 154
- perturbed growth 101
- Ph chromosome 185
- phenotypically identical donor 380
- phenotyping of ALL colony cells 146
- Philadelphia (Ph) chromosome 1, 12
- photolysis 286, 287
- photosensitisation 282
- plasma membrane 283
- plateau phase 100, 107
- plating efficiencies ALL 144
- population doubling time 101
- population kinetics of leukemic cells 77
- pre-B-ALL 52, 114, 299
- preparative treatment regimen 314
- probability of complete remission duration 156
- prognostic factor analysis 149
- prognostic factors in nAML 148
- prothiocyctic ALL 123
- pseudodiploid 185
- purging of marrow 62

- quality of life 330

- Ragi cell line 251, 288
- ras mutations 44
- ras oncogenes 43
- rat leukemia model 76
- rearrangements 2
- Reh-6 cell line 251
- reinduction treatment for AML 162
- relative fluorescence intensity 68
- remission induction 170
- renal failure 311
- residual clonogenic ALL cells 146
- restriction enzyme map 14
- ricin 277, 278, 376
- Rm124 monoclonal antibody 76
- RNA analysis 13
- rotovirus 311

- S-phase fractions 80
- serum bilirubin and alkaline phosphatase 154
- sheep red cells 338
- SK-N-MC cell line 288
- SK-N-SH cell line 288
- Southern blot analysis 24, 51
- Southern blotting 5
- soybean lectin fractionation 345
- specific breakpoints 1
- surface antigens of BNML cell lines 89
- surface makers 68
- surface marker analysis 58
- suspension culture ALL cells 142
- syngeneic marrow transplantation in acute leukemia 311

- T cell antigen receptor 51
- T cell receptor gene 53
- t(15q;17q) inv. 16 155
- T-ALL 114, 198, 200, 201, 208, 299
- T-cell depletion 345, 355
- T-cell regeneration 328
- T-depleted marrow 323
- T-lymphocyte depletion 323
- T101 antibody 276, 277, 278
- T6 antigen 115, 121
- TA-1 antibody 276, 277, 278
- TdT 134
- TdT positive T cell malignancies 123
- TdT+ peripheral blood cells 138
- temperature elevation at malities of BUN and serum creatinine 154
- terminal deoxynucleotidyl transferase (TdT) 115, 117
- therapy level L(t) 101
- three parameter flow cytometry 86
- time delay T 101
- total lymphoid irradiation (TLI) 339

transplantation 63
treatment of residual disease in AML 167

UCHL1 antibody 276, 277, 278
unclassified ALL 299
unperturbed growth 100

veno-occlusive disease of the liver 311
viral infections 311, 330
vitro T-cell depletion 328
VP-16 249, 254, 257